Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$353,403
+$8,952 QoQ
Shares Held
2,255
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#1,045
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Tyche Wealth Partners LLC holds $18,163,637 across 7 Drug Manufacturers - General names. NVS ranks #7 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
22,399 | $5,688,674 | |
| 2 | LLY |
ELI LILLY & Co
|
4,653 | $5,580,948 | |
| 3 | ABBV |
AbbVie Inc.
|
17,400 | $4,378,536 | |
| 4 | MRK |
Merck & Co., Inc.
|
8,583 | $1,102,915 | |
| 5 | AMGN |
Amgen Inc
|
1,495 | $541,369 | |
| 6 | PFE |
Pfizer Inc
|
21,503 | $517,792 | |
| 7 | NVS |
Novartis AG
This page
|
2,255 | $353,403 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $353,403 | 2,255 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $344,451 | 2,255 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $310,207 | 2,250 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $288,540 | 2,250 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $272,272 | 2,250 | Shares | Sole | 2025-07-23 | |
| 2025-03-31 | $250,161 | 2,244 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $218,655 | 2,247 | Shares | Sole | 2025-01-27 | |
| 2024-09-30 | $258,449 | 2,247 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $238,896 | 2,244 | Shares | Sole | 2024-07-18 | |
| 2024-03-31 | $216,385 | 2,237 | Shares | Sole | 2024-04-23 | |
| 2023-12-31 | $215,772 | 2,137 | Shares | Sole | 2024-01-30 | |
| No filing history on record for this holder in this stock. | ||||||